The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study. The TIMI Investigators
BR Chaitman,
B Thompson,
MD Wittry,
D Stump,
WP Hamilton,
LD Hillis,
JG Dwyer,
RE Solomon,
and
GL Knatterud
Maryland Medical Research Institute, Incorporated, Baltimore 21210.
The impact of age on hospital mortality, incidence of major hemorrhagic events and transfusion requirements was examined in 756 patients with acute myocardial infarction enrolled in the Thrombolysis in Myocardial Infarction (TIMI) Phase I, open label studies and the TIMI Phase II pilot study. The mortality rate significantly increased with age and was 3.5%, 11.5% and 12% in patients less than 65, 65 to 69 and 70 to 76 years of age, respectively (p less than 0.001). Logistic regression analyses selected female gender, diabetes mellitus, extensive coronary artery disease, history of congestive heart failure, continuing chest pain immediately after recombinant tissue-type plasminogen activator (rt-PA) administration, low systolic blood pressure at the time of admission and advanced age as variables predictive of in-hospital death. The incidence of major hemorrhagic events among patients not undergoing cardiac surgery during hospitalization was 8.7%, 14.5% and 24.7% in patients aged less than 65, 65 to 69 and greater than or equal to 70 years, respectively (p less than 0.001). The majority of hemorrhages were secondary to cardiac catheterization or puncture wounds. Variables related to a major hemorrhagic event included protocol, age, rt-PA dose/kg body weight and elevated diastolic blood pressure on admission. Of five intracranial bleeding events, three occurred in patients greater than 65 years. Transfusion requirements significantly increased with age (p less than 0.001). Reperfusion status at 90 min in the TIMI Phase I and open label studies A to C was similar in the three age groups studied and ranged from 60% to 71%.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
|
|
 
A. M. Miller, M. S. Boro, N. E. Korman, and J. B. Davoren
Provider and pharmacist responses to warfarin drug-drug interaction alerts: a study of healthcare downstream of CPOE alerts
JAMIA,
December 1, 2011;
18(Suppl_1):
i45 - i50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Nicolau, C. V. Serrano Jr., S. A.C. Garzon, and J. A.F. Ramires
Prognosis of acute myocardial infarction in the thrombolytic era: medical evaluation is still valuable
Eur J Heart Fail,
October 1, 2001;
3(5):
569 - 576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gottlieb, U. Goldbourt, V. Boyko, G. Barbash, L. Mandelzweig, H. Reicher-Reiss, S. Stern, and S. Behar
Improved Outcome of Elderly Patients (>=75 Years of Age) With Acute Myocardial Infarction From 1981-1983 to 1992-1994 in Israel
Circulation,
January 21, 1997;
95(2):
342 - 350.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. Kellett and J. Clarke
Comparison of "Accelerated" Tissue Plasminogen Activator with Streptokinase for Treatment of Suspected Myocardial Infarction
Med Decis Making,
October 1, 1995;
15(4):
297 - 310.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. J. Doorey, E. L. Michelson, and E. J. Topol
Thrombolytic Therapy of Acute Myocardial Infarction: Keeping the Unfulfilled Promises
JAMA,
December 2, 1992;
268(21):
3108 - 3114.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. J. Krone
The Role of Risk Stratification in the Early Management of a Myocardial Infarction
Ann Intern Med,
February 1, 1992;
116(3):
223 - 237.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. R. Cragg, H. Z. Friedman, J. D. Bonema, I. A. Jaiyesimi, R. G. Ramos, G. C. Timmis, W. W. O'Neill, and T. L. Schreiber
Outcome of Patients with Acute Myocardial Infarction Who Are Ineligible for Thrombolytic Therapy
Ann Intern Med,
August 1, 1991;
115(3):
173 - 177.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. H. Gurwitz, R. J. Goldberg, and J. M. Gore
Coronary Thrombolysis for the Elderly?
JAMA,
April 3, 1991;
265(13):
1720 - 1723.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. W. M. Muller and E. J. Topol
Selection of Patients with Acute Myocardial Infarction for Thrombolytic Therapy
Ann Intern Med,
December 15, 1990;
113(12):
949 - 960.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. C. Becker and J. S. Alpert
The Impact of Medical Therapy on Hemorrhagic Complications Following Coronary Artery Bypass Grafting
Arch Intern Med,
October 1, 1990;
150(10):
2016 - 2021.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. C. Becker and J. M. Gore
Tissue Plasminogen Activator and Intracranial Hemorrhage
Ann Intern Med,
April 15, 1990;
112(8):
630 - 630.
[Abstract]
[PDF]
|
|
|
|
|
|
|
RISKS OF THROMBOLYSIS RISE WITH AGE
Journal Watch (General),
November 28, 1989;
1989(1128):
9 - 9.
[Full Text]
|
|
|
|
